Skip to main content

Table 4 Grade 3 ≤ adverse events during the second-line chemotherapy

From: Second-line chemotherapy after early disease progression during first-line chemotherapy containing bevacizumab for patients with metastatic colorectal cancer

Adverse event BBP group (%) Non-BBP group (%)
Hematological
 Neutropenia 6 (16.2) 6 (24.0)
 Anemia 1 (2.7) 4 (16.0)
 Thrombocytopenia 1 (2.7) 1 (4.0)
Non-hematological
 Fatigue 0 (0) 1 (4.0)
 Decreased appetite 2 (5.4) 2 (8.0)
 Diarrhea 2 (5.4) 0 (0)
 Hypertension 1 (2.7) 0 (0)
 Proteinuria 1 (2.7) 0 (0)
 Gastrointestinal perforation 1 (2.7) 1 (4.0)
 Bleeding 1 (2.7) 1 (4.0)
 Venous thromboembolic 1 (2.7) 0 (0)
 Cerebral infarction 1 (2.7) 0 (0)
 Ileus 1 (2.7) 1 (4.0)
 Hepatic infection 0 (0) 1 (4.0).
 Febrile neutropenia 1 (2.7) 0 (0)